Posted by Michael Wonder on 20 May 2026
FDA accepts sNDA and grants priority review to Aqneursa for ataxia-telangiectasia
19 May 2026 - IntraBio today announced that the US FDA has accepted for review its supplemental new drug application for Aqneursa (levacetylleucine) for the treatment of ataxia-telangiectasia in adults and paediatric patients.
The FDA simultaneously granted priority review and assigned a PDUFA target action date of 19 September 2026.
